JAK1 (phospho-Tyr1022) Antibody
- Known as:
- JAK1 (phosphorilated-Tyr1022) Antibody
- Catalog number:
- abx000235
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- JAK1 (phospho-Tyr1022) Antibody
Related genes to: JAK1 (phospho-Tyr1022) Antibody
- Gene:
- JAK1 NIH gene
- Name:
- Janus kinase 1
- Previous symbol:
- JAK1B
- Synonyms:
- JAK1A, JTK3
- Chromosome:
- 1p31.3
- Locus Type:
- gene with protein product
- Date approved:
- 1992-04-16
- Date modifiied:
- 2016-10-05
Related products to: JAK1 (phospho-Tyr1022) Antibody
Related articles to: JAK1 (phospho-Tyr1022) Antibody
- In rheumatoid arthritis (RA), dysregulated proliferation signaling in fibroblast-like synoviocytes (FLS) undermines synovial homeostasis. Attenuation of the interaction between G protein-coupled receptor kinase 2 (GRK2) and Janus kinase 1 (JAK1) facilitates activation of signal transducer and activator of transcription 3 (STAT3), thereby driving excessive cell proliferation. Nevertheless, it remains unclear whether GRK2 directly associates with JAK1 and which specific binding interfaces are responsible for restraining FLS hyperproliferation and preserving synovial equilibrium. Accordingly, this study aimed to clarify the underlying inhibitory mechanism. Our findings demonstrate that disruption of the GRK2-JAK1 interaction enhances STAT3 signaling, leading to aberrant proliferation of RA FLS. Mechanistic analyses revealed that the C-terminal region of GRK2 directly interacts with the Src homology 2 (SH2) domain of JAK1, thereby suppressing STAT3 activation. This inhibitory interaction critically depends on the arginine residues R466 and R506 within the JAK1 SH2 domain. Notably, pharmacological inhibition of GRK2 strengthened the GRK2-JAK1 association and attenuated STAT3 activation in both in vitro and in vivo models. As a consequence, excessive FLS proliferation and the expression of pro-inflammatory and lipid mediators were reduced to near-physiological levels, ultimately restoring synovial homeostasis through a mechanism distinct from that of conventional JAK inhibitors. Collectively, these results uncover a previously unrecognized negative regulatory axis involving GRK2 and JAK1 and highlight the essential role of GRK2 in controlling FLS proliferation and synovial homeostasis in RA, suggesting a promising therapeutic strategy that may avoid the adverse effects associated with direct JAK inhibition. - Source: PubMed
Publication date: 2026/09/30
Han ChenchenZuo ShujunJiang LipingGuo FuyuanGuo HaozhouTan HongzhengSun HuazhanWang WeikangGu JintaoXiong GaoxinMa YangWei Wei - To evaluate the inhibitory effect of anwulignan (ANW) on malignant biological behaviors of gastric cancer cells and explore its underlying molecular mechanism. - Source: PubMed
Liu XinyueZhang KeniQiao TongYin LinZhang LongtaoCheng XinkeWang BenCao JinlinGeng ZhijunZhao Hao - Sequential lymphoid neoplasms are rare and diagnostically challenging, with a variable clonal relationship. Here we present the case of a 59-year-old woman with mediastinal grey zone lymphoma (MGZL), who, shortly after achieving complete remission, developed a subsequent cutaneous neoplasm. Comparative molecular studies were performed using high-throughput sequencing (HTS), which demonstrated that both neoplasms shared high-allele-frequency EP300:p.P2333L and PTPRK:p.R532K variants. In addition, each neoplasm harboured private, mutually exclusive variants-NFKBIA:p.R245Sfs*39 and BTG2:c.142+5G>C in the MGZL and JAK1:p.Q562* and JAK1:p.G1097D in the skin. Integrating the clinical course with HTS, we diagnosed lymphomatoid papulosis and excluded relapse of the MGZL. Interestingly, the shared variants were likely germline rather than clonal, suggesting they created a permissive background predisposing to two independent transforming events along the B- and T-cell lineages. Molecular studies may help to reveal the genetic basis of composite lymphomas and to resolve diagnostically discordant, complex presentations. - Source: PubMed
Publication date: 2026/09/29
Tapken Maria JJuskevicius DariusBalestri IlariaBollinger Claudia RuthAlborelli IlariaKurscheid SebastianCajacob LucianWilli NielsHäusermann PeterDirnhofer StefanTzankov Alexandar - Selective JAK1 inhibition can control inflammation in immune-mediated diseases with reduced haematological toxicity. IN-115314, a selective JAK1 inhibitor, was evaluated in a first-in-human, randomized, double-blind, placebo-controlled study in healthy participants for safety, pharmacokinetics (PK) and pharmacodynamics (PD). - Source: PubMed
Publication date: 2026/09/28
Huh Ki YoungKang JaeguJang HaerimKang DeborahJang In-JinLee Seung Hwan - Phosphoenolpyruvate carboxykinase 1 (PCK1) has been shown to have signalling functions beyond gluconeogenesis. However, its role in gastric cancer is unclear. - Source: PubMed
Publication date: 2026/09/28
Nie JiaoLi TianYang XingyuBi WenxinLu WeishengZhang JinmingLi ChunmeiGuan YuqingPeng XiangWang PingLiu FengShen RulingLi ChenglinDu Chao